---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-22-025761"
form_type: "8-K"
ticker: "PBYI"
cik: "0001401667"
company_name: "PUMA BIOTECHNOLOGY, INC."
filed_at: "2022-11-03T23:59:59+00:00"
generated_at: "2026-06-22T08:35:38.795565+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Puma Biotechnology Q3 net loss narrows to $0.4M; raises FY 2022 NERLYNX revenue guidance

## Summary
- Q3 product revenue $54.3M, up 25% YoY from $43.4M; net loss $0.4M ($0.01/share) vs $44.7M loss in Q3 2021.
- Non-GAAP adjusted net income $2.5M ($0.05/share) vs adjusted loss of $40.4M a year ago.
- Raises FY 2022 product revenue guidance to $194-$196M from prior $180-$190M; net income guidance $7-$9M.
- In-licensed alisertib (aurora kinase A inhibitor) from Takeda for $7M upfront; plans initial trials in HR+ breast cancer and small cell lung cancer.
- Cash and marketable securities $78.0M at Sep 30, 2022; operating cash flow $17.3M in Q3.

## SEC filing metadata
- accession: 0001437749-22-025761
- form_type: 8-K
- ticker: PBYI
- cik: 0001401667
- company_name: PUMA BIOTECHNOLOGY, INC.
- filed_at: 2022-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401667/000143774922025761/0001437749-22-025761-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401667/000143774922025761/pbyi20221101_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-22-025761
- JSON: https://secwatch.observer/filing/0001437749-22-025761.json
- Plain text: https://secwatch.observer/filing/0001437749-22-025761.txt

## Key facts
- Earnings Releases
  PUMA BIOTECHNOLOGY, INC. reported third quarter ended September 30, 2022 results: revenue $54.3 million, net income Net loss of $0.4 million, or $0.01 per share, EPS $0.01 per share. Guidance raised.
  - Period: third quarter ended September 30, 2022
  - Revenue: $54.3 million
  - Net income: Net loss of $0.4 million, or $0.01 per share
  - EPS: $0.01 per share
  - Guidance: raised
  - Result: reported results
  source text: quarter of 2021. Product revenue, net consists entirely of sales revenue from NERLYNX®, Puma’s first commercial product. Product revenue, net in the third quarter of 2022 was $54.3 million, compared to $43.4 million in the third quarter of 2021. Product revenue, net in the first nine months of 2022 was $146.3 million, compared to $138.1 million in the first nine
  evidence_url: https://www.sec.gov/Archives/edgar/data/1401667/000143774922025761/0001437749-22-025761-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.